Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05636436

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Herpes Zoster DNA Virus Infections Herpesviridae Infections Infections Varicella Zoster Virus Infection Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Yanjin District Center for Disease Control and Prevention

Xinxiang, Henan, 453200, China

About this study

The clinical trial will be a single-center, randomized, blind, controlled study in which two dose levels of vaccine will be tested in healthy adults aged 18 to 49 years and 50 years and older, with progression from low dose level to high dose level and younger age group to the older age group based on assessment of safety and tolerability. The younger cohort (aged 18 to 49 years) will consist of 60 subjects, 30 per dose level, and these 30 subjects will be randomized into three subgroups, including vaccine group, adjuvant group and normal saline group, with randomization ratio of 2:2:1. The older cohort (aged 50 years and older) will consist of 72 subjects, 36 per dose level, and these 36 subjects will be randomized into four subgroups, including vaccine group, adjuvant group, Shingrix® group and normal saline group, with randomization ratio of 2:2:1:1.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Permanent residents aged 18 years and above;
  • Subjects voluntarily agree to participate in the study and signed an informed consent;
  • Be able to participate in all scheduled visits and comply with the protocol requirements.

Exclusion criteria

  • Axillary temperature>37.0℃;
  • History of herpes zoster within 5 years before vaccination;
  • Prior vaccination with chickenpox vaccine or herpes zoster vaccine;
  • Female participant who is pregnant ( urine pregnancy test was positive) or breastfeeding, or has pregnancy plans within 1 year after the last vaccination;
  • Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;
  • Receipt of immunoglobulin or intravenous immunoglobulin within 3 months before vaccination;
  • Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination;
  • A known allergy to any components of the study vaccine (especially allergic to aminoglycoside antibiotics), or history of severe allergy to any previous vaccination;
  • History of convulsions, epilepsy, encephalopathy (such as congenital brain dysplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, nerve tissue damage caused by chemical drug poisoning, etc.) or mental illness and family history;
  • Asplenia or functional asplenia, or splenectomy caused by any condition;
  • Primary or secondary impairment of immune function or diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;
  • Receipt of immunosuppressive therapy within 3 months before vaccination (such as long-term use of systemic glucocorticoid ≥14 days, dose ≥2mg/kg/day or ≥20mg/day prednisone or equivalent dose), but inhaled, intra-articular and topical steroids are acceptable;
  • Severe cardiovascular disease(eg. Pulmonary heart disease, Pulmonary Edema); Severe liver or kidney disease; or diabetes with complication;
  • History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;
  • Abnormal blood pressure during physical examination before vaccination (systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg);
  • Abnormal and clinically significant laboratory test results as determined by the investigator before vaccination;
  • Current or history of alcohol and/or drug abuse;
  • Any condition that, in the opinion the investigator, may affect the safety of the subject or the evaluation of the study results.

Treatment and study plan

Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)

Biological

0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.

High Dose Recombinant Herpes Zoster Vaccine (CHO cells)

Biological

0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.

Low dose adjuvant

Biological

0.5 mL per dose, containing low dose MA105 adjuvant.

High dose adjuvant

Biological

0.5 mL per dose, containing high dose MA105 adjuvant.

Positive control

Biological

0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.

Other names: Shingrix®

Placebo

Biological

0.5 mL per dose, containing 4.5 mg sodium chloride.

Other names: Saline for injection

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: Within 30 minutes after each vaccination.

    Incidence and severity of adverse events within 30 minutes after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.

  2. The incidence and severity of adverse events

    Time frame: Within 7 days after each vaccination.

    Incidence and severity of adverse events within 7 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.

  3. The incidence and severity of adverse events

    Time frame: Day 8 to 30 after each vaccination.

    Incidence and severity of adverse events during Day 8 to 30 after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.

  4. The incidence and severity of adverse events

    Time frame: Within 30 days after each vaccination.

    Incidence and severity of adverse events within 30 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.

  5. Incidence of abnormal and clinically significant laboratory test results

    Time frame: Day 4 after each vaccination .

    Laboratory test includes hematology, blood biochemistry and urine analysis.

Secondary outcomes

  1. Incidence of Serious Adverse Event

    Time frame: From the first vaccination to 12 months after full vaccination (From Day 0 to Day 420).

    Incidence of Serious Adverse Event (SAE) from the first vaccination to 12 months after full vaccination.

  2. Potential Immune Mediated Disorder

    Time frame: From the first vaccination to 12 months after full vaccination (From Day 0 to Day 420).

    Incidence of Potential Immune Mediated Disorder (pIMD) from the first vaccination to 12 months after full vaccination.

  3. Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody

    Time frame: Prior to each vaccination (Day 0, Day 60).

    Measured by ELISA.

  4. Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody

    Time frame: Day 14 after each vaccination (Day 14, Day 74).

    Measured by ELISA.

  5. Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody

    Time frame: Month 1 after each vaccination (Day 30, Day 90).

    Measured by ELISA.

  6. Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody

    Time frame: Month 6 and 12 after the second vaccination (Day 240, Day 420).

    Measured by ELISA.

  7. Seroconversion rate of anti-gE antibody and anti-VZV antibody

    Time frame: Prior to the second vaccination (Day 60).

    Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was <Cut-off value at baseline.

  8. Seroconversion rate of anti-gE antibody and anti-VZV antibody

    Time frame: Day 14 after each vaccination (Day 14, Day 74).

    Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was <Cut-off value at baseline.

  9. Seroconversion rate of anti-gE antibody and anti-VZV antibody

    Time frame: Month 1 after each vaccination (Day 30, Day 90).

    Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was <Cut-off value at baseline.

  10. Positive rate of anti-gE antibody and anti-VZV antibody

    Time frame: Prior to each vaccination (Day 0, Day 60).

    Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value.

  11. Positive rate of anti-gE antibody and anti-VZV antibody

    Time frame: Day 14 after each vaccination (Day 14, Day 74).

    Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value.

  12. Positive rate of anti-gE antibody and anti-VZV antibody

    Time frame: Month 1 after each vaccination (Day 30, Day 90).

    Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value.

  13. Positive rate of anti-gE antibody and anti-VZV antibody

    Time frame: Month 6 and 12 after the second vaccination (Day 240, Day 420).

    Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value.

  14. Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration

    Time frame: Prior to the second vaccination (Day 60).

    The antibody concentration prior to the second vaccination compared with that at baseline (Day 0).

  15. Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration

    Time frame: Day 14 after each vaccination (Day 14, Day 74).

    The antibody concentration at Day 14 after each vaccination compared with that at baseline (Day 0).

  16. Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration

    Time frame: Month 1 after each vaccination (Day 30, Day 90)

    The antibody concentration at 1 month after each vaccination compared with that at baseline (Day 0).

  17. Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration

    Time frame: Prior to the second vaccination (Day 60).

    The antibody concentration prior to the second vaccination compared with that at baseline (Day 0).

  18. Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration

    Time frame: Day 14 after each vaccination (Day 14, Day 74).

    The antibody concentration at Day 14 after each vaccination compared with that at baseline (Day 0).

  19. Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration

    Time frame: Month 1 after each vaccination (Day 30, Day 90).

    The antibody concentration at month 1 after each vaccination compared with that at baseline (Day 0).

  20. Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker

    Time frame: Prior to the first vaccination (Day 0).

    The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L).

  21. Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker

    Time frame: Month 1 after the second vaccination (Day 90).

    The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L).

  22. Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker

    Time frame: Month 6, 12 after the second vaccination (Day 240, Day 420).

    The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L).

  23. Cellular immune response

    Time frame: Prior to the first vaccination (Day 0).

    Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells <Cut-off value at baseline.

  24. Cellular immune response

    Time frame: Month 1 after the second vaccination (Day 90).

    Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells <Cut-off value at baseline.

  25. Cellular immune response

    Time frame: Month 6, 12 after the second vaccination (Day 240, Day 420)

    Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells <Cut-off value at baseline.

Sponsors and collaborators

Lead sponsor

MAXVAX Biotechnology Limited Liability Company

Industry

Collaborators

  • Henan Center for Disease Control and Prevention

Registry information

Official study title

A Phase I, Single Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 5, 2022
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.